Objective: Osteopontin (OPN), a phosphorylated sialoprotein, has been shown to overexpress in a variety of cancers and to contribute tumor progression and metastasis by increasing cell migration and adhesion. In the current study, we aimed to investigate the prognostic and predictive role of OPN in patients with advanced gastric cancer.

Methods: A total of 42 consecutive chemonaive patients with advanced gastric cancer and 29 healthy controls were included. The patients were treated with a modified DCF regimen. The blood samples were obtained before each chemotherapy cycle from the patients and once from the healthy controls. The plasma OPN is measured by ELISA.

Results: The overall response and disease stabilization rates were 25% and 72%, respectively. The median serum OPN level of the patient group was significantly higher compared to healthy controls (176.9 ng/ml (range: 41.5 -521.4) vs 64.3 ng/ml (range 42.1-105.3 ng/ml), p<0.0001). The median overall survival time was 7.0 ± 1.1 (95% CI: 4.9–9.2) months and 1-year overall survival rate was 20.8%. The patients who responded to mDCF had lower plasma OPN levels than the non-responding ones (110.7±29.3 ng/mL, 211.9±24.4 ng/mL respectively, p=0.002). The performance status and the plasma OPN levels were found to be significant factors for overall survival in the multivariate analysis (p=0.004 and 0.016, respectively).

Conclusion: The serum OPN seems to be a novel significant prognostic and predictive factor in patients with advanced gastric cancer who were treated with DCF regimen.

目的：骨桥蛋白 (OPN) 是一种磷酸化的唾液酸蛋白，已被证明在多种癌症中过度表达，并通过增加细胞迁移和粘附来促进肿瘤进展和转移。在目前的研究中，我们旨在调查 OPN 在晚期胃癌患者中的预后和预测作用。

方法：共纳入42例连续化疗的晚期胃癌患者和29例健康对照。患者接受改良的 DCF 方案治疗。在每个化疗周期之前从患者那里获得血液样本，并从健康对照中获得一次。通过ELISA测量血浆OPN。

结果：总体缓解率和疾病稳定率分别为 25% 和 72%。与健康对照组相比，患者组的中位血清 OPN 水平显着升高（176.9 ng/ml（范围：41.5 -521.4）对 64.3 ng/ml（范围 42.1-105.3 ng/ml），p<0.0001）。中位总生存时间为 7.0 ± 1.1 (95% CI: 4.9-9.2) 个月，1 年总生存率为 20.8%。对 mDCF 有反应的患者血浆 OPN 水平低于无反应的患者（分别为 110.7±29.3 ng/mL、211.9±24.4 ng/mL，p=0.002）。在多变量分析中发现体能状态和血浆 OPN 水平是总体存活率的重要因素（分别为 p = 0.004 和 0.016）。

结论：血清 OPN 似乎是 DCF 方案治疗的晚期胃癌患者新的重要预后和预测因素。